Doot RK, Young AJ, Nasrallah IN, Wetherill RR, Siderowf A, Mach RH, Dubroff JG.  [18F]NOS PET brain imaging suggests elevated neuroinflammation in idiopathic Parkinson’s disease. Cells. 2022 Sep; 11(19):3081.

Zuroff L, Wisseb LEM, Glenn T, Xie S, Nasrallah I, Habes M, Dubroff J, de Flores R, Xie L, Yushkevich P, Doshi J, Davatsikos C, Wolka DA, Dasa S, Mechanic-Hamilton D. Self- and partner-reported subjective memory complaints: association with objective cognitive impairment and risk of decline. JAD reports 2022 Jul; 6(1): 411-430.

Aamodt WW, Dubroff JG, Cheng G, Taylor B, Wood S, Duda JE, and Morley JF. Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced parkinsonism. npj Parkinson's Disease. 2022 Apr; 8(1):53.

Phillips JS, Nitchie FJ 4th, Da Re F, Olm CA, Cook PA, McMillan CT, Irwin DJ, Gee JC, Dubroff JG, Grossman M, Nasrallah IM. Rates of longitudinal change in 18 F-flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease.  Alzheimers Dement 2022 Jun;18(6):1235-1247.

Das SR, Lyu X, Duong MT, Xie L, McCollum L, de Flores R, DiCalogero M, Irwin DJ, Dickerson BC, Nasrallah IM, Yushkevich PA, Wolk DA. Tau-Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Ann Neurol. 2021 Nov;90(5):751-762.

Duong MT, Chen YJ, Doot RK, Young AJ, Lee H, Cai J, Pilania A, Wolk DA, Nasrallah IM. Astrocyte activation imaging with 11C-acetate and amyloid PET in mild cognitive impairment due to Alzheimer pathology.  Nucl Med Commun. 2021 Nov 1;42(11):1261-1269.

Kini LG, Thaker AA, Hadar PN, Shinohara RT, Brown MG, Dubroff JG, Davis KA.Quantitative [18] FDG PET asymmetry features predict long-term seizure recurrence in refractory epilepsy. Epilepsy Behav 2021 Mar;116:107714.

Thaker AA, Chien AL, Dubroff JGFrontiers in Neuroscience Imaging: Whole-Body PET. PET Clin. 2021 Jan;16(1):137-146.

Coughlin DG, Phillips JS, Roll E, Peterson C, Lobrovich R, Rascovsky K, Ungrady M, Wolk DA, Das S, Weintraub D, Lee EB, Trojanowski JQ, Shaw LM, Vaishnavi S, Siderowf A, Nasrallah IM, Irwin DJ, McMillan CT; Alzheimer’s Disease Neuroimaging Initiative. Multimodal in vivo and postmortem assessments of tau in Lewy body disorders. Neurobiol Aging. 2020 Dec;96:137-147.

Dolui S, Li Z, Nasrallah IM, Detre JA, Wolk DA. Arterial spin labeling versus 18 F-FDG-PET to identify mild cognitive impairment.  Neuroimage Clin. 2020;25:102146. 

Nabavizadeh SA, Nasrallah IM, Pryma DA. Flare Phenomenon in O-(2-[ 18 F]-Fluoroethyl)-L-Tyrosine PET After Resection of Gliomas: Potential Contribution from Postoperative Ischemia.  J Nucl Med. 2020 Dec;61(12):1851-1852.  

Pantel AR, Viswanath V, Daube-Witherspoon ME, Dubroff JG, Muehllehner G, Parma MJ, Pryma DA, Schubert EK, Mankoff DA, Karp JS. PennPET Explorer: Human Imaging on a Whole-Body Imager. J Nucl Med. 2020 Jan;61(1):144-151.

Doot RK, Dubroff JG, Labban KJ, Mach RH. Selectivity of probes for PET imaging of dopamine D3 receptors. Neurosci Lett. 2019 Jan 19;691:18-25.

Phillips JS, Das SR, McMillan CT, Irwin DJ, Roll EE, Da Re F, Nasrallah IM, Wolk DA, Grossman M. Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease. Hum Brain Mapp. 2018 Feb;39(2):691-708.

Nasrallah IM, Chen YJ, Hsieh MK, Phillips JS, Ternes K, Stockbower GE, Sheline Y, McMillan CT, Grossman M, Wolk DA. 18F-Flortaucipir PET/MRI Correlations in Nonamnestic and Amnestic Variants of Alzheimer Disease. J Nucl Med. 2018 Feb;59(2):299-306.

Booij J, Dubroff J, Pryma D, Yu J, Agarwal R, Lakhani P, Kuo PH. Diagnostic Performance of the Visual Reading of 123I-Ioflupane SPECT Images With or Without Quantification in Patients With Movement Disorders or Dementia. J Nucl Med. 2017 Nov;58(11):1821-1826.

Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM, Van Deerlin VM, Trojanowski JQ, Chen-Plotkin AS, Hurtig HI, Siderowf AD, Dubroff JG, Weintraub D. Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS One. 2017 May 25;12(5): e0177924.

Morley JF, Cheng G, Dubroff JG, Wood S, Wilkinson JR, Duda JE. Olfactory Impairment Predicts Underlying Dopaminergic Deficit in Presumed Drug-Induced Parkinsonism.Mov Disord Clin Pract. 2016 Nov 28;4(4):603-606.

Dubroff JG, Doot RK, Falcone M, Schnoll RA, Ray R, Tyndale RF, Brody AL, Hou C, Schmitz A, Lerman C. Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism. J Nucl Med. 2015 Nov;56(11):1724-9.

Dubroff JG, Nasrallah IM. Will PET amyloid imaging lead to overdiagnosis of Alzheimer dementia? Acad Radiol. 2015 Aug;22(8):988-94.

Nayate AP, Dubroff JG, Schmitt JE, Nasrallah I, Kishore R, Mankoff D, Pryma DA; Alzheimer's Disease Neuroimaging Initiative. Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation. AJNR Am J Neuroradiol. 2015 Jul;36(7):1237-44.

Doty RL, Nsoesie MT, Chung I, Osman A, Pawasarat I, Caulfield J, Hurtig H, Silas J, Dubroff J, Duda JE, Ying GS, Tekeli H, Leon-Sarmiento FE.T aste function in early stage treated and untreated Parkinson's disease. J Neurol. 2015 Mar;262(3):547-57.

Doty RL, Gandhi SS, Osman A, Hurtig HI, Pawasarat I, Beals E, Chung I, Dubroff J, Newberg A, Ying GS, Leon-Sarmiento FE. Point pressure sensitivity in early stage Parkinson's disease. Physiol Behav. 2015 Jan;138:21-7.

Doty RL, Beals E, Osman A, Dubroff J, Chung I, Leon-Sarmiento FE, Hurtig H, Ying GS. Suprathreshold odor intensity perception in early-stage Parkinson's disease. Mov Disord. 2014 Aug;29(9):1208-12.

Nasrallah IM, Wolk DA. Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. J Nucl Med. 2014 Dec;55(12):2003-11.

Nasrallah I and Dubroff J. An overview of PET neuroimaging. Semin Nucl Med. 2013 Nov;43(6):449-61.